BC Extra | Jan 22, 2020
Company News

Jan. 21 Company Quick Takes: First BCMA-targeted therapy gets Priority Review from FDA; plus Roche-Seattle Genetics, AZ-Merck, Chi-Med

Priority Review for GSK's anti-BCMA therapy in MM  GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said FDA granted Priority Review to a BLA for belantamab mafodotin to treat fourth-line relapsed or refractory multiple myeloma in patients who have...
BioCentury | Jan 18, 2020
Product Development

Charting a course to intercepting Type I diabetes

Arguably, the most important innovations on the horizon for Type I diabetes would replace the insulin-producing cells patients have lost or prevent at-risk individuals from losing the cells in the first place. With Provention planning...
BC Extra | Jan 13, 2020
Clinical News

Adaptimmune rises on early promise for SPEAR TCR cell therapies in solid tumors

Cancer cell therapy play Adaptimmune gained $2.66 (200%) to $3.99 on Monday after announcing a new set of data for its SPEAR T cell therapies in four different solid tumor indications. The announcement by Adaptimmune...
BioCentury | Jan 13, 2020
Finance

All chips on immuno-oncology is not a good gamble

While first-generation immuno-oncology therapies are only the tip of the iceberg of what immune reprogramming promises to do for patients, the massive investment in the space has entered bubble territory, with the inflating number of...
BioCentury | Jan 11, 2020
Finance

Why buysiders say 2020 could be the year of the CNS

A pair of CNS approvals in the final days of 2019 has only added to the growing momentum buysiders were already tracking for 2020 in the once neglected disease area. Positive regulatory signals are converging...
BC Extra | Jan 9, 2020
Financial News

Aspect to engineer therapeutic tissues with $20M series A

After spending its early years validating its 3-D bioprinting technology via disease modeling in drug discovery partnerships, Aspect Biosystems raised a $20 million series A round to develop the engineered tissues as therapeutics. New investor...
BC Extra | Jan 8, 2020
Company News

Management tracks: Fred Hutch taps BMS CSO Lynch; plus GSK, Rubius, Provention, Antengene, Revitope, Compugen, Wellington, Adamas, Arcturus and Turnstone

Fred Hutchinson Cancer Research Center hired Thomas Lynch as president and director, effective next month. Lynch was CSO of Bristol-Myers Squibb Co. (NYSE:BMY). He succeeds Gary Gilliland, who announced in September his plans to step...
BC Extra | Jan 4, 2020
Company News

Management tracks: Fountain Medical taps Zhen as CEO; plus DBV, Momenta reveal CFO succession plans

Fountain Medical Development Ltd. named Ling Zhen as CEO and co-chairman. Zhen joins the clinical CRO from Draper Dragon Venture Group, where he was a partner focused on biopharmaceutical and medical technology investments. Zhen is...
BC Extra | Dec 30, 2019
Company News

FDA approves Lynparza as first PARP inhibitor for pancreatic cancer

FDA’s approval of Lynparza for pancreatic cancer notches a trio of firsts: the first drug approved for the indication based on PFS rather than OS, the first PARP inhibitor approved to treat the disease, and...
BC Extra | Dec 27, 2019
Company News

With Zejula’s third local approval, Zai ready for mainland China launch

China’s approval of Zejula gives Zai Lab its first approval in mainland China and allows the company to start marketing the PARP inhibitor in the largest of the three markets in which it holds rights....
Items per page:
1 - 10 of 8719
BC Extra | Jan 22, 2020
Company News

Jan. 21 Company Quick Takes: First BCMA-targeted therapy gets Priority Review from FDA; plus Roche-Seattle Genetics, AZ-Merck, Chi-Med

Priority Review for GSK's anti-BCMA therapy in MM  GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said FDA granted Priority Review to a BLA for belantamab mafodotin to treat fourth-line relapsed or refractory multiple myeloma in patients who have...
BioCentury | Jan 18, 2020
Product Development

Charting a course to intercepting Type I diabetes

Arguably, the most important innovations on the horizon for Type I diabetes would replace the insulin-producing cells patients have lost or prevent at-risk individuals from losing the cells in the first place. With Provention planning...
BC Extra | Jan 13, 2020
Clinical News

Adaptimmune rises on early promise for SPEAR TCR cell therapies in solid tumors

Cancer cell therapy play Adaptimmune gained $2.66 (200%) to $3.99 on Monday after announcing a new set of data for its SPEAR T cell therapies in four different solid tumor indications. The announcement by Adaptimmune...
BioCentury | Jan 13, 2020
Finance

All chips on immuno-oncology is not a good gamble

While first-generation immuno-oncology therapies are only the tip of the iceberg of what immune reprogramming promises to do for patients, the massive investment in the space has entered bubble territory, with the inflating number of...
BioCentury | Jan 11, 2020
Finance

Why buysiders say 2020 could be the year of the CNS

A pair of CNS approvals in the final days of 2019 has only added to the growing momentum buysiders were already tracking for 2020 in the once neglected disease area. Positive regulatory signals are converging...
BC Extra | Jan 9, 2020
Financial News

Aspect to engineer therapeutic tissues with $20M series A

After spending its early years validating its 3-D bioprinting technology via disease modeling in drug discovery partnerships, Aspect Biosystems raised a $20 million series A round to develop the engineered tissues as therapeutics. New investor...
BC Extra | Jan 8, 2020
Company News

Management tracks: Fred Hutch taps BMS CSO Lynch; plus GSK, Rubius, Provention, Antengene, Revitope, Compugen, Wellington, Adamas, Arcturus and Turnstone

Fred Hutchinson Cancer Research Center hired Thomas Lynch as president and director, effective next month. Lynch was CSO of Bristol-Myers Squibb Co. (NYSE:BMY). He succeeds Gary Gilliland, who announced in September his plans to step...
BC Extra | Jan 4, 2020
Company News

Management tracks: Fountain Medical taps Zhen as CEO; plus DBV, Momenta reveal CFO succession plans

Fountain Medical Development Ltd. named Ling Zhen as CEO and co-chairman. Zhen joins the clinical CRO from Draper Dragon Venture Group, where he was a partner focused on biopharmaceutical and medical technology investments. Zhen is...
BC Extra | Dec 30, 2019
Company News

FDA approves Lynparza as first PARP inhibitor for pancreatic cancer

FDA’s approval of Lynparza for pancreatic cancer notches a trio of firsts: the first drug approved for the indication based on PFS rather than OS, the first PARP inhibitor approved to treat the disease, and...
BC Extra | Dec 27, 2019
Company News

With Zejula’s third local approval, Zai ready for mainland China launch

China’s approval of Zejula gives Zai Lab its first approval in mainland China and allows the company to start marketing the PARP inhibitor in the largest of the three markets in which it holds rights....
Items per page:
1 - 10 of 8719